Asad Niazi, MD, MPH

Physician — Weight Loss Medicine

Specialties: Obesity Medicine · Telemedicine · Weight Management

About Asad

Dr. Asad Niazi is a licensed physician and Master of Public Health practicing through the Beluga Health 50-state telemedicine network. At Trimi Health, Dr. Niazi reviews patient eligibility for compounded GLP-1 weight management therapy, evaluating each new patient's medical history, BMI, and weight-related comorbidities (type 2 diabetes, hypertension, sleep apnea, dyslipidemia, cardiovascular disease) against FDA labeling thresholds and obesity-medicine clinical guidelines. His clinical focus includes obesity medicine, telemedicine-based chronic care, and metabolic health. He works within Trimi's evidence-based protocols, which align with the Endocrine Society's 2024 Obesity Pharmacotherapy Guideline and the AACE Comprehensive Type 2 Diabetes Algorithm 2024. Dr. Niazi's review covers contraindications such as personal or family history of medullary thyroid carcinoma, MEN 2 syndrome, pancreatitis, and severe gastrointestinal disease, and confirms that prescriptions are dispensed only by Trimi's named 503A community sterile compounding pharmacies (VialsRx, Texas State Board pharmacy license #35264, and GreenwichRx). He emphasizes patient education on common GLP-1 adverse effects (nausea, vomiting, gallbladder events, acute kidney injury risk if severe GI side effects cause dehydration) and the importance of dose titration to maximize tolerability. Trimi's compounded medications are prepared per individual prescription and are not FDA-approved as drugs; the active ingredients (semaglutide, tirzepatide) are FDA-approved in the corresponding brand formulations (Wegovy/Ozempic and Mounjaro/Zepbound).

Experience

Active board-certified clinician

Board Certifications

Active medical license

Licensed in 1 state

Questions about Asad's role at Trimi

What patients commonly ask about clinician review at Trimi Health.

Who is Dr. Asad Niazi?

Dr. Asad Niazi is a licensed physician and Master of Public Health (MPH) who reviews patient eligibility for compounded GLP-1 weight management therapy at Trimi Health. He practices through the Beluga Health 50-state telemedicine network, evaluating each new patient's medical history, BMI, and weight-related comorbidities before any compounded prescription is issued.

What does Dr. Niazi review when a patient submits an intake?

He reviews the patient's full medical history, current medications, prior weight-loss interventions, BMI calculation, and weight-related comorbidities (type 2 diabetes, hypertension, sleep apnea, dyslipidemia, cardiovascular disease). He confirms eligibility against FDA labeling thresholds (BMI ≥30, or BMI ≥27 with a weight-related comorbidity) and obesity-medicine clinical guidelines, then screens for contraindications.

What contraindications does Dr. Niazi screen for?

Personal or family history of medullary thyroid carcinoma (MTC), Multiple Endocrine Neoplasia type 2 (MEN 2) syndrome, history of pancreatitis, severe gastrointestinal disease, severe renal impairment, current pregnancy or breastfeeding, and any prior serious hypersensitivity reaction to GLP-1 receptor agonists. These contraindications align with FDA prescribing information for semaglutide and tirzepatide.

How does Beluga Health work with Trimi?

Beluga Health is Trimi's clinical infrastructure partner — a multistate medical service organization (MSO) and 50-state telemedicine physician network. Dr. Niazi is one of the licensed physicians in Beluga's clinician network who handles patient reviews on Trimi's platform. Beluga maintains state-by-state physician licensing and credentialing so Trimi can offer care nationwide.

Who actually prescribes the medication?

A licensed US physician within the Beluga Health clinician network — Dr. Niazi or another credentialed prescriber — writes the prescription after reviewing the intake. Compounded medications are then dispensed by Trimi's 503A community sterile compounding pharmacy partners: VialsRx (Texas State Board pharmacy license #35264) and GreenwichRx.

Are Trimi's compounded medications FDA-approved?

Trimi's compounded preparations are prepared per individual prescription by 503A community sterile compounding pharmacies and are not themselves FDA-approved as drugs. The active ingredients — semaglutide and tirzepatide — are FDA-approved in the corresponding brand-name finished products (Wegovy/Ozempic and Mounjaro/Zepbound respectively). Compounded versions are prepared from FDA-listed active pharmaceutical ingredients.

What states is Dr. Niazi licensed in?

Dr. Niazi's individual licensure is listed in the Licensed States card on this page. Through the broader Beluga Health network, Trimi has access to licensed prescribers in all 50 US states — if Dr. Niazi is not the assigned reviewer for your state, another credentialed Beluga physician handles your intake under the same clinical protocols.

What clinical guidelines does Dr. Niazi follow?

His review aligns with the Endocrine Society's 2024 Obesity Pharmacotherapy Guideline, the AACE Comprehensive Type 2 Diabetes Algorithm 2024, and FDA prescribing information for the relevant active ingredients. He emphasizes patient education on common GLP-1 adverse effects (nausea, vomiting, gallbladder events, acute kidney injury risk from dehydration) and the importance of dose titration for tolerability.

Treatment information reviewed under this clinical network

Programs and clinical guides for which Asad and other clinicians in the Beluga Health network review eligibility.

Get matched with a board-certified provider

Provider review within 24 hours. Compounded semaglutide from $99/month, tirzepatide from $125/month.